Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)

Authors

  • Midas B. Mulder Department of Clinical Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
  • Erwin Birnie Department of Statistics and Education, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands; Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  • Caroline van Dijck – van Boetzelaer Department of Outpatient Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
  • Gert-Jan van de Geijn Department of Clinical Chemistry (KCHL), Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
  • Egbert Boevé Department of Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
  • Elsbeth M. Westerman Department of Clinical Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
  • Paul Hamberg Department of Oncology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands

DOI:

https://doi.org/10.1080/0284186X.2020.1862908

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2021-04-03

How to Cite

Mulder, M. B., Birnie, E., Dijck – van Boetzelaer, C. van, van de Geijn, G.-J., Boevé, E., Westerman, E. M., & Hamberg, P. (2021). Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial). Acta Oncologica, 60(4), 539–543. https://doi.org/10.1080/0284186X.2020.1862908

Issue

Vol. 60 No. 4 (2021): Acta Oncologica

Section

Articles